Suraksha Diagnostic IPO Date, Price, GMP, Review, Details, Issue Date, Lot Size, Allotment, Subscription Status
Suraksha Diagnostic IPO is set to open on November 29, 2024, and will close on December 3, 2024. This is a Book Built Issue IPO, aiming to raise around ₹846.25 crores. The offering includes a fresh issue and an offer for sale (OFS) of up to 1,91,89,330 equity shares, each with a face value of ₹2.
IPO Highlights
- Price Band: ₹420–₹441 per share
- Lot Size: Minimum 34 shares (₹14,994)
- Issue Type: Book Built
- Listing: BSE & NSE
- Retail Investor Quota: 35%
- QIB Quota: 50%
- HNI Quota: 15%
- Allotment Date: December 4, 2024
- Listing Date: December 6, 2024
Financial Overview
Suraksha Diagnostic has demonstrated strong financial growth:
- FY 2023 Revenue: ₹190.13 crores
- FY 2024 Revenue: ₹218.71 crores (+15% YoY)
- FY 2023 Profit: ₹6.07 crores
- FY 2024 Profit: ₹23.13 crores (+280% YoY)
This reflects consistent profitability and improved margins, making it a promising IPO for long-term investors.
Market Lot Details
Investors can bid for a minimum of 34 shares and a maximum of 442 shares under the retail category.
| Category | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Minimum | 1 | 34 | ₹14,994 |
| Retail Maximum | 13 | 442 | ₹1,94,922 |
| S-HNI Minimum | 14 | 476 | ₹2,09,916 |
| S-HNI Maximum | 66 | 2,244 | ₹9,89,604 |
About the Company
Incorporated in 2005, Suraksha Diagnostic is a leading diagnostic service provider based in East India. Its offerings include pathology and radiology tests, with a robust portfolio of over 2,300 tests, such as advanced biochemistry, molecular pathology, and histopathology.
- Network: 1,522 permanent staff
- CAGR (FY22-24): 20.87% in revenue
- Strengths: Dominance in Eastern India, strong financial performance, and extensive diagnostic solutions.
IPO Objectives
- To carry out the Offer for Sale by selling shareholders.
- To achieve the benefits of listing equity shares on stock exchanges.
Peer Comparison
The company competes with established names such as Dr. Lal PathLabs, Metropolis Healthcare, and Vijaya Diagnostic.
| Company | EPS | PE Ratio | RoNW | NAV |
|---|---|---|---|---|
| Dr. Lal PathLabs | ₹43.05 | 68.66 | 20.35% | ₹221.47 |
| Metropolis Healthcare | ₹24.95 | 82.57 | 12.26% | ₹213.98 |
| Vijaya Diagnostic | ₹11.62 | 67.65 | 19.77% | ₹64.21 |
Important Dates
| Event | Date |
|---|---|
| IPO Open Date | November 29, 2024 |
| IPO Close Date | December 3, 2024 |
| Basis of Allotment | December 4, 2024 |
| Refunds Initiated | December 5, 2024 |
| Credit to Demat | December 5, 2024 |
| Listing Date | December 6, 2024 |
Registrar and Lead Managers
- Registrar: KFin Technologies Limited
- Lead Manager: Nuvama Wealth and Investment Limited
For more details, visit the company’s website: www.surakshanet.com
Disclaimer: Investors are advised to evaluate financial performance, growth prospects, and risks before applying for the IPO.
